Belimumab: A Guide to Its Use in Systemic Lupus Erythematosus |
| |
Authors: | Lesley J Scott Celeste B Burness Paul L McCormack |
| |
Institution: | Adis, Auckland, New Zealand. |
| |
Abstract: | Belimumab (Benlysta?), a fully human recombinant IgG1λ monoclonal antibody that inhibits the binding of soluble B lymphocyte stimulator to B cells, is indicated for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite receiving standard therapy. In multinational trials, significantly more belimumab recipients than placebo recipients achieved an SLE Responder Index response at 52 weeks. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|